Grace Therapeutics, Inc 8-K/A, filed Nov 5, 2021
Grace Therapeutics, Inc. (GRCE)
About this 8-K/A
Grace Therapeutics, Inc filed this 8-K/A on November 5, 2021, reporting on events of August 26, 2021.
Items reported
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form
(Amendment No. 1)
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
| (Address of Principal Executive Offices) (Zip Code) |
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Explanatory Note.
Item 9.01. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
The financial statements required by this Item with respect to the Merger described in Item 2.01 in the Original 8-K, as modified hereby, were previously filed as part of as part of the Registration Statement on Form S-4 filed by Acasti with the SEC on June 30, 2021, as amended by Amendment no. 1 thereto filed with the SEC on July 13, 2021, link to which is found in Exhibit 99.1 hereto.
(b) Pro forma financial information.
The pro forma financial information required by this Item with respect to the Merger described in Item 2.01 in the Original 8-K, as modified hereby, were previously filed as part of the Registration Statement on Form S-4 filed by Acasti with the SEC on June 30, 2021, as amended by Amendment no. 1 thereto filed with the SEC on July 13, 2021, a link to which is found in Exhibit 99.2 hereto.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACASTI PHARMA INC. | ||
| Date: November 5, 2021 | By: | /s/ Jan D’Alvise |
| Jan D’Alvise | ||
| Chief Executive Officer | ||
Exhibit 99.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Form 8-K/A of Acasti Pharma, Inc. to be filed on or about November 5, 2021 and to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239538) and on Form S-8 (No. 333-191383 and No. 333-227476) of Acasti Pharma, Inc. of our report dated March 26, 2021, on our audits of the financial statements of Grace Therapeutics, Inc. (“Grace”) as of December 31, 2020 and 2019 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning Grace’s ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in the Registration Statement on Form S-3.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Iselin, New Jersey
November 5, 2021